PAUL SADAMA: Open Payments
NPI 1609452077 · NEW YORK, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,090 in 16 payments from 7 companies in 2025. Trend: 2023 $511 · 2024 $1,030 · 2025 $3,090
Consulting: $2,588Food & beverage: $503
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 3 | $2,750 |
| Stemline Therapeutics Inc. | 4 | $104 |
| Novartis Pharmaceuticals Corporation | 3 | $68 |
| TerSera Therapeutics LLC | 2 | $61 |
| Merck Sharp & Dohme LLC | 2 | $44 |
| AstraZeneca Pharmaceuticals LP | 1 | $32 |
| JAZZ PHARMACEUTICALS INC. | 1 | $31 |
Products named: RYBREVANT, Orserdu, KISQALI, Zoladex, KEYTRUDA, ENHERTU, ZEPZELCA.
Industry payments across NY — which companies pay providers there.
